The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer.

Trial Profile

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Tasquinimod (Primary) ; Cabazitaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms CATCH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2015 After an interim analysis of the phase III 10TASQ10 study showed that tasquinimod did not improve overall survival, and efficacy results together with preliminary safety data did not support a positive benefit-risk balance in this population, Active Biotech and Ipsen announced their decision to discontinue the development of tasquinimod in prostate cancer, according to a media release.
    • 16 Apr 2015 Status changed from recruiting to discontinued, according to a media release from Active Biotech and Ipsen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top